Interleukin-34 cancels anti-tumor immunity by PARP inhibitor

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors improve progression-free survival in BRCA1-associated ovarian cancer but therapeutic resistance eventually develops.
• Interleukin-34 (IL-34) is a poor prognostic factor in several cancers, including ovarian cancer, and contributes to chemotherapy resistance.
• IL-34's role in PARP inhibitor resistance, potentially via tumor microenvironment (TME) modulation, requires investigation.

Purpose of the Study:

• To evaluate IL-34 as a prognostic factor in ovarian serous carcinoma.
• To investigate the impact of IL-34 on the efficacy of PARP inhibitor therapy in BRCA1-associated ovarian cancer.
• To elucidate the mechanism by which IL-34 confers PARP inhibitor resistance.

Main Methods:

• Analysis of The Cancer Genome Atlas (TCGA) data for IL-34 expression and prognosis in ovarian serous carcinoma.
• Utilizing CRISPR-Cas9 genome editing in a mouse model to assess PARP inhibitor efficacy with and without IL-34.
• Investigating the role of the XCR1+ DC-CD8+ T cell axis in mediating anti-tumor immunity.

Main Results:

• High IL34 expression is an independent poor prognostic factor in ovarian serous carcinoma, correlating with shorter overall survival.
• PARP inhibitor therapy enhances anti-tumor immunity via the XCR1+ DC-CD8+ T cell axis in BRCA1-associated ovarian cancer.
• The presence of IL-34 abrogates the anti-tumor immune response induced by PARP inhibitors.

Conclusions:

• Tumor-derived IL-34 promotes an immunosuppressive TME, leading to PARP inhibitor therapeutic resistance.
• IL-34 plays a critical pathological role in ovarian cancer progression and resistance.
• IL-34 represents a potential therapeutic target to overcome PARP inhibitor resistance in ovarian cancer.